1 M.S. Song, L. Salmena, P.P. PandolfiThe functions and regulation of the PTEN tumour suppressor Nat Rev Mol Cell Biol, 13 (5) (2012), pp. 283-296

2 P.A. Steck, M.A. Pershouse, S.A. Jasser, et al.Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat Genet, 15 (4) (1997), pp. 356-362

3 D.M. Li, H. SunTEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta Cancer Res, 57 (11) (1997), pp. 2124-2129

4 J. Li, C. Yen, D. Liaw, et al.PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science, 275 (5308) (1997), pp. 1943-1947

5 P. Kechagioglou, R.M. Papi, X. Provatopoulou, et al.Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression Anticancer Res, 34 (3) (2014), pp. 1387-1400

6 A. Di Cristofano, B. Pesce, C. Cordon-Cardo, et al.Pten is essential for embryonic development and tumour suppression Nat Genet, 19 (4) (1998), pp. 348-355

7 V. Stambolic, A. Suzuki, J.L. de la Pompa, et al.Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell, 95 (1) (1998), pp. 29-39

8 A. Suzuki, J.L. de la Pompa, V. Stambolic, et al.High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice Curr Biol, 8 (21) (1998), pp. 1169-1178

9 K. Podsypanina, L.H. Ellenson, A. Nemes, et al.Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems Proc Natl Acad Sci U S A, 96 (4) (1999), pp. 1563-1568

10 H. Sun, R. Lesche, D.M. Li, et al.PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3, 4, 5,-trisphosphate and Akt/protein kinase B signaling pathway Proc Natl Acad Sci U S A, 96 (11) (1999), pp. 6199-6204

11 J. Liliental, S.Y. Moon, R. Lesche, et al.Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases Curr Biol, 10 (7) (2000), pp. 401-404

12 V. Stambolic, M.S. Tsao, D. MacPherson, et al.High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice Cancer Res, 60 (13) (2000), pp. 3605-3611

13 S.A. Backman, V. Stambolic, A. Suzuki, et al.Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease Nat Genet, 29 (4) (2001), pp. 396-403

14 M.C. Hollander, G.M. Blumenthal, P.A. DennisPTEN loss in the continuum of common cancers, rare syndromes and mouse models Nat Rev Cancer, 11 (4) (2011), pp. 289-301

15 J. Gu, M. Tamura, K.M. YamadaTumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways J Cell Biol, 143 (5) (1998), pp. 1375-1383

16 D.M. Li, H. SunPTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells Proc Natl Acad Sci U S A, 95 (26) (1998), pp. 15406-15411

17 J. Puc, R. ParsonsPTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells Cell Cycle, 4 (7) (2005), pp. 927-929

18 J.O. Lee, H. Yang, M.M. Georgescu, et al.Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association Cell, 99 (3) (1999), pp. 323-334

19 L.C. Cantley, B.G. NeelNew insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc Natl Acad Sci U S A, 96 (8) (1999), pp. 4240-4245

20 Y. Yin, W.H. ShenPTEN: a new guardian of the genome Oncogene, 27 (41) (2008), pp. 5443-5453

21 R.B. Campbell, F. Liu, A.H. RossAllosteric activation of PTEN phosphatase by phosphatidylinositol 4, 5-bisphosphate J Biol Chem, 278 (36) (2003), pp. 33617-33620

22 S.M. Walker, N.R. Leslie, N.M. Perera, et al.The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif Biochem J, 379 (Pt 2) (2004), pp. 301-307

23 M.M. Georgescu, K.H. Kirsch, T. Akagi, et al.The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region Proc Natl Acad Sci U S A, 96 (18) (1999), pp. 10182-10187

24 A.S. Fanning, J.M. AndersonProtein modules as organizers of membrane structure Curr Opin Cell Biol, 11 (4) (1999), pp. 432-439

25 S. Das, J.E. Dixon, W. ChoMembrane-binding and activation mechanism of PTEN Proc Natl Acad Sci U S A, 100 (13) (2003), pp. 7491-7496

26 W.H. Shen, A.S. Balajee, J. Wang, et al.Essential role for nuclear PTEN in maintaining chromosomal integrity Cell, 128 (1) (2007), pp. 157-170

27 M.P. Myers, I. Pass, I.H. Batty, et al.The lipid phosphatase activity of PTEN is critical for its tumor supressor function Proc Natl Acad Sci U S A, 95 (23) (1998), pp. 13513-13518

28 M.P. Myers, J.P. Stolarov, C. Eng, et al.P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase Proc Natl Acad Sci U S A, 94 (17) (1997), pp. 9052-9057

29 M.L. Sulis, R. ParsonsPTEN: from pathology to biology Trends Cell Biol, 13 (9) (2003), pp. 478-483

30 N.R. Leslie, C.P. DownesPTEN function: how normal cells control it and tumour cells lose it Biochem J, 382 (Pt 1) (2004), pp. 1-11

31 I. Sansal, W.R. SellersThe biology and clinical relevance of the PTEN tumor suppressor pathway J Clin Oncol, 22 (14) (2004), pp. 2954-2963

32 T. Maehama, J.E. DixonThe tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate J Biol Chem, 273 (22) (1998), pp. 13375-13378

33 A. Klippel, W.M. Kavanaugh, D. Pot, et al.A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain Mol Cell Biol, 17 (1) (1997), pp. 338-344

34 B.P. Ziemba, C. Pilling, V. Calleja, et al.The PH domain of phosphoinositide-dependent kinase-1 exhibits a novel, phospho-regulated monomer-dimer equilibrium with important implications for kinase domain activation: single-molecule and ensemble studies Biochemistry, 52 (28) (2013), pp. 4820-4829

35 B.D. Manning, L.C. CantleyAKT/PKB signaling: navigating downstream Cell, 129 (7) (2007), pp. 1261-1274

36 N. Nakamura, S. Ramaswamy, F. Vazquez, et al.Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN Mol Cell Biol, 20 (23) (2000), pp. 8969-8982

37 S.R. Datta, H. Dudek, X. Tao, et al.Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell, 91 (2) (1997), pp. 231-241

38 L.D. Mayo, D.B. DonnerA phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus Proc Natl Acad Sci U S A, 98 (20) (2001), pp. 11598-11603

39 K. Inoki, Y. Li, T. Zhu, et al.TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol, 4 (9) (2002), pp. 648-657

40 E. Vander Haar, S.I. Lee, S. Bandhakavi, et al.Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nat Cell Biol, 9 (3) (2007), pp. 316-323

41 A. Sekulić, C.C. Hudson, J.L. Homme, et al.A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells Cancer Res, 60 (13) (2000), pp. 3504-3513

42 K.M. Dodd, J. Yang, M.H. Shen, et al.mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 Oncogene, 34 (17) (2015), pp. 2239-2250

43 J.L. Luo, W. Tan, J.M. Ricono, et al.Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin Nature, 446 (7136) (2007), pp. 690-694

44 S. Sheng, M. Qiao, A.B. PardeeMetastasis and AKT activation J Cell Physiol, 218 (3) (2009), pp. 451-454

45 J.A. Diehl, M. Cheng, M.F. Roussel, et al.Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization Genes Dev, 12 (22) (1998), pp. 3499-3511

46 N. Chalhoub, S.J. BakerPTEN and the PI3-kinase pathway in cancer Annu Rev Pathol, 4 (2009), pp. 127-150

47 L. Salmena, A. Carracedo, P.P. PandolfiTenets of PTEN tumor suppression Cell, 133 (3) (2008), pp. 403-414

48 Y.R. Lee, M. Chen, P.P. PandolfiThe functions and regulation of the PTEN tumour suppressor: new modes and prospects Nat Rev Mol Cell Biol, 19 (9) (2018), pp. 547-562

49 S. Agrawal, R. Pilarski, C. EngDifferent splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN Hum Mol Genet, 14 (16) (2005), pp. 2459-2468

50 D.J. Marsh, J.B. Kum, K.L. Lunetta, et al.PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome Hum Mol Genet, 8 (8) (1999), pp. 1461-1472

51 X. Zhou, H. Hampel, H. Thiele, et al.Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes Lancet, 358 (9277) (2001), pp. 210-211

52 D.J. Marsh, V. Coulon, K.L. Lunetta, et al.Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation Hum Mol Genet, 7 (3) (1998), pp. 507-515

53 F. Molinari, M. FrattiniFunctions and regulation of the PTEN gene in colorectal cancer Front Oncol, 3 (2013), p. 326

54 M.H. Tan, J. Mester, C. Peterson, et al.A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands Am J Hum Genet, 88 (1) (2011), pp. 42-56

55 D. Liaw, D.J. Marsh, J. Li, et al.Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome Nat Genet, 16 (1) (1997), pp. 64-67

56 L.M.L. Chow, S.J. BakerPTEN function in normal and neoplastic growth Cancer Lett, 241 (2) (2006), pp. 184-196

57 C. Bazzichetto, F. Conciatori, M. Pallocca, et al.PTEN as a prognostic/predictive biomarker in cancer: an unfulfilled promise? Cancers, 11 (4) (2019), p. 435

58 L.C. Trotman, X. Wang, A. Alimonti, et al.Ubiquitination regulates PTEN nuclear import and tumor suppression Cell, 128 (2007), pp. 141-156

59 A. Mirmohammadsadegh, A. Marini, S. Nambiar, et al.Epigenetic silencing of the PTEN gene in melanoma Cancer Res, 66 (13) (2006), pp. 6546-6552

60 J.M. García, J. Silva, C. Peña, et al.Promoter methylation of the PTEN gene is a common molecular change in breast cancer Genes Chromosomes Cancer, 41 (2) (2004), pp. 117-124

61 J. Lu, H.W. Jeong, N. Kong, et al.Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex PLoS One, 4 (5) (2009), p. e5577

62 H.Y. Zhang, F. Liang, Z.L. Jia, et al.PTEN mutation, methylation and expression in breast cancer patients Oncol Lett, 6 (2013), pp. 161-168

63 V. Stambolic, D. MacPherson, D. Sas, et al.Regulation of PTEN transcription by p53 Mol Cell, 8 (2) (2001), pp. 317-325

64 R.A. Moorehead, C.V. Hojilla, I. De Belle, et al.Insulin-like growth factor-II regulates PTEN expression in the mammary gland J Biol Chem, 278 (50) (2003), pp. 50422-50427

65 L. Patel, I. Pass, P. Coxon, et al.Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN Curr Biol, 11 (10) (2001), pp. 764-768

66 W. Zhang, N. Wu, Z. Li, et al.PPARγ activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404 Cancer Biol Ther, 5 (8) (2006), pp. 1008-1014

67 J.T. Whelan, S.L. Forbes, F.E. BertrandCBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression Cell Cycle, 6 (1) (2007), pp. 80-84

68 D. Xia, H. Srinivas, Y.H. Ahn, et al.Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NFκB-dependent pathway J Biol Chem, 282 (6) (2007), pp. 3507-3519

69 L. Mahimainathan, F. Das, B. Venkatesan, et al.Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN Diabetes, 55 (7) (2006), pp. 2115-2125

70 J.Y.C. Chow, K.T. Quach, B.L. Cabrera, et al.RAS/ERK modulates TGFβ-regulated PTEN expression in human pancreatic adenocarcinoma cells Carcinogenesis, 28 (11) (2007), pp. 2321-2327

71 K. Hettinger, F. Vikhanskaya, M.K. Poh, et al.c-Jun promotes cellular survival by suppression of PTEN Cell Death Differ, 14 (2) (2007), pp. 218-229

72 J.Y. Lee, M.B. Kang, S.H. Jang, et al.Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition Oncogene, 28 (6) (2009), pp. 824-831

73 L.B. Song, J. Li, W.T. Liao, et al.The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells J Clin Invest, 119 (12) (2009), pp. 3626-3636

74 M. Escrivà, S. Peiró, N. Herranz, et al.Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis Mol Cell Biol, 28 (5) (2008), pp. 1528-1540

75 Y. Tay, S.J. Song, P.P. PandolfiThe lilliputians and the giant: an emerging oncogenic microRNA network that suppresses the PTEN tumor suppressor in vivo MicroRNA, 2 (2) (2013), pp. 127-136

76 F. Meng, R. Henson, H. Wehbe-Janek, et al.MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer Gastroenterology, 133 (2) (2007), pp. 647-658

77 J.G. Zhang, J.J. Wang, F. Zhao, et al.MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC) Clin Chim Acta, 411 (11–12) (2010), pp. 846-852

78 L. Poliseno, L. Salmena, L. Riccardi, et al.Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation Sci Signal, 3 (117) (2010), p. ra29

79 L. Ciuffreda, C. Di Sanza, U.C. Incani, et al.The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms J Mol Med, 90 (6) (2012), pp. 667-679

80 P. Mu, Y.C. Han, D. Betel, et al.Genetic dissection of the miR-17∼92 cluster of microRNAs in Myc-induced B-cell lymphomas Genes Dev, 23 (24) (2009), pp. 2806-2811

81 L. Poliseno, L. Salmena, J. Zhang, et al.A coding-independent function of gene and pseudogene mRNAs regulates tumour biology Nature, 465 (7301) (2010), pp. 1033-1038

82 S.J. Miller, D.Y. Lou, D.C. Seldin, et al.Direct identification of PTEN phosphorylation sites FEBS Lett, 528 (1–3) (2002), pp. 145-153

83 J. Torres, R. PulidoThe tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation J Biol Chem, 276 (2) (2001), pp. 993-998

84 F. Vazquez, S.R. Grossman, Y. Takahashi, et al.Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex J Biol Chem, 276 (52) (2001), pp. 48627-48630

85 H. Mehenni, N. Lin-Marq, K. Buchet-Poyau, et al.LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes Hum Mol Genet, 14 (15) (2005), pp. 2209-2219

86 A.M. Al-Khouri, Y. Ma, S.H. Togo, et al.Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta J Biol Chem, 280 (42) (2005), pp. 35195-35202

87 E.K. Yim, G. Peng, H. Dai, et al.Rak functions as a tumor suppressor by regulating PTEN protein stability and function Cancer Cell, 15 (4) (2009), pp. 304-314

88 Z. Li, X. Dong, Z. Wang, et al.Regulation of PTEN by rho small GTPases Nat Cell Biol, 7 (4) (2005), pp. 399-404

89 X. Wang, L.C. Trotman, T. Koppie, et al.NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN Cell, 128 (1) (2007), pp. 129-139

90 N. Amodio, M. Scrima, L. Palaia, et al.Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas Am J Pathol, 177 (5) (2010), pp. 2622-2634

91 K. Okumura, M. Mendoza, R.M. Bachoo, et al.PCAF modulates PTEN activity J Biol Chem, 281 (36) (2006), pp. 26562-26568

92 S.R. Lee, K.S. Yang, J. Kwon, et al.Reversible inactivation of the tumor suppressor PTEN by H2O2 J Biol Chem, 277 (23) (2002), pp. 20336-20342

93 Y. Takahashi, F.C. Morales, E.L. Kreimann, et al.PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling EMBO J, 25 (4) (2006), pp. 910-920

94 X. Wu, K. Hepner, S. Castelino-Prabhu, et al.Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2 Proc Natl Acad Sci U S A, 97 (8) (2000), pp. 4233-4238

95 E. Lima-Fernandes, H. Enslen, E. Camand, et al.Distinct functional outputs of PTEN signalling are controlled by dynamic association with β-arrestins EMBO J, 30 (13) (2011), pp. 2557-2568

96 M.T. van Diepen, M. Parsons, C.P. Downes, et al.MyosinV controls PTEN function and neuronal cell size Nat Cell Biol, 11 (10) (2009), pp. 1191-1196

97 K. Okumura, M. Zhao, R.A. Depinho, et al.Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor Proc Natl Acad Sci U S A, 102 (8) (2005), pp. 2703-2706

98 Y.C. Kim, H. Kitaura, T. Taira, et al.Oxidation of DJ-1-dependent cell transformation through direct binding of DJ-1 to PTEN Int J Oncol, 35 (6) (2009), pp. 1331-1341

99 B. Fine, C. Hodakoski, S. Koujak, et al.Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a Science, 325 (5945) (2009), pp. 1261-1265

100 L. He, A. Ingram, A.P. Rybak, et al.Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells J Clin Invest, 120 (6) (2010), pp. 2094-2108

101 L. He, C. Fan, A. Kapoor, et al.α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells Nat Commun, 2 (2011), p. 307

102 S.J. Leevers, B. Vanhaesebroeck, M.D. WaterfieldSignalling through phosphoinositide 3-kinases: the lipids take centre stage Curr Opin Cell Biol, 11 (2) (1999), pp. 219-225

103 S.M. Planchon, K.A. Waite, C. EngThe nuclear affairs of PTEN J Cell Sci, 121 (Pt 3) (2008), pp. 249-253

104 O. WarburgOn respiratory impairment in cancer cells Science, 124 (3215) (1956), pp. 269-270

105 M.G. Vander Heiden, L.C. Cantley, C.B. ThompsonUnderstanding the Warburg effect: the metabolic requirements of cell proliferation Science, 324 (5930) (2009), pp. 1029-1033

106 I. Garcia-Cao, M.S. Song, R.M. Hobbs, et al.Systemic elevation of PTEN induces a tumor-suppressive metabolic state Cell, 149 (1) (2012), pp. 49-62

107 A. Ortega-Molina, A. Efeyan, E. Lopez-Guadamillas, et al.Pten positively regulates brown adipose function, energy expenditure, and longevity Cell Metabol, 15 (3) (2012), pp. 382-394

108 T. Vellai, D. McCulloch, D. Gems, et al.Effects of sex and insulin/insulin-like growth factor-1 signaling on performance in an associative learning paradigm in Caenorhabditis elegans Genetics, 174 (1) (2006), pp. 309-316

109 J.T. Wong, P.T.W. Kim, J.W. Peacock, et al.Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity Diabetologia, 50 (2) (2007), pp. 395-403

110 N. Nakashima, P.M. Sharma, T. Imamura, et al.The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes J Biol Chem, 275 (17) (2000), pp. 12889-12895

111 V.A. Mosser, Y. Li, M.J. QuonPTEN does not modulate GLUT4 translocation in rat adipose cells under physiological conditions Biochem Biophys Res Commun, 288 (4) (2001), pp. 1011-1017

112 F. Morani, S. Phadngam, C. Follo, et al.PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells J Mol Endocrinol, 53 (2) (2014), pp. 247-258

113 Y. Horie, A. Suzuki, E. Kataoka, et al.Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas J Clin Invest, 113 (12) (2004), pp. 1774-1783

114 M. Raftopoulou, S. Etienne-Manneville, A. Self, et al.Regulation of cell migration by the C2 domain of the tumor suppressor PTEN Science, 303 (5661) (2004), pp. 1179-1181

115 M. Tamura, J. Gu, K. Matsumoto, et al.Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN Science, 280 (5369) (1998), pp. 1614-1617

116 M.J. Park, M.S. Kim, I.C. Park, et al.PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation Cancer Res, 62 (21) (2002), pp. 6318-6322

117 J. Gu, M. Tamura, R. Pankov, et al.Shc and FAK differentially regulate cell motility and directionality modulated by PTEN J Cell Biol, 146 (2) (1999), pp. 389-403

118 F. Martin-Belmonte, A. Gassama, A. Datta, et al.PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42 Cell, 128 (2) (2007), pp. 383-397

119 S. Aquila, M. Santoro, A. Caputo, et al.The tumor suppressor PTEN as molecular switch node regulating cell metabolism and autophagy: implications in immune system and tumor microenvironment Cells, 9 (7) (2020), p. 1725

120 Z. Lin, L. Huang, S.L. Li, et al.PTEN loss correlates with T cell exclusion across human cancers BMC Cancer, 21 (2021), p. 429

121 T. Vidotto, F.P. Saggioro, T. Jamaspishvili, et al.PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of Ido1 and infiltrating FoxP3+ T regulatory cells Prostate, 79 (9) (2019), pp. 969-979

122 Y. Yang, Y. Bai, Y. He, et al.PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer Clin Cancer Res, 24 (4) (2018), pp. 834-846

123 K. Kurose, K. Gilley, S. Matsumoto, et al.Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas Nat Genet, 32 (3) (2002), pp. 355-357

124 R. Kalluri, M. ZeisbergFibroblasts in cancer Nat Rev Cancer, 6 (5) (2006), pp. 392-401

125 A.J. Trimboli, C.Z. Cantemir-Stone, F. Li, et al.Pten in stromal fibroblasts suppresses mammary epithelial tumours Nature, 461 (7267) (2009), pp. 1084-1091

126 A. Bronisz, J. Godlewski, J.A. Wallace, et al.Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320 Nat Cell Biol, 14 (2) (2011), pp. 159-167

127 H.D. Skinner, J.Z. Zheng, J. Fang, et al.Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling J Biol Chem, 279 (44) (2004), pp. 45643-45651

128 W. Shen, H.L. Li, L. Liu, et al.Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer Eur Rev Med Pharmacol Sci, 21 (11) (2017), pp. 2596-2603

129 S. Wen, J. Stolarov, M.P. Myers, et al.PTEN controls tumor-induced angiogenesis Proc Natl Acad Sci U S A, 98 (8) (2001), pp. 4622-4627

130 O. Gimm, A. Perren, L.P. Weng, et al.Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors Am J Pathol, 156 (5) (2000), pp. 1693-1700

131 A. Perren, L.P. Weng, A.H. Boag, et al.Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast Am J Pathol, 155 (4) (1999), pp. 1253-1260

132 J. Puc, M. Keniry, H.S. Li, et al.Lack of PTEN sequesters CHK1 and initiates genetic instability Cancer Cell, 7 (2) (2005), pp. 193-204

133 M.S. Song, A. Carracedo, L. Salmena, et al.Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner Cell, 144 (2) (2011), pp. 187-199

134 X.S. Liu, B. Song, B.D. Elzey, et al.Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation J Biol Chem, 286 (41) (2011), pp. 35795-35800

135 D.J. Freeman, A.G. Li, G. Wei, et al.PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms Cancer Cell, 3 (2) (2003), pp. 117-130

136 Y. Ogawara, S. Kishishita, T. Obata, et al.Akt enhances Mdm2-mediated ubiquitination and degradation of p53 J Biol Chem, 277 (24) (2002), pp. 21843-21850

137 D. Zecchin, C. Moore, F. Michailidis, et al.Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer EMBO Mol Med, 12 (8) (2020), Article e11987

138 N. Owusu-Brackett, M. Zhao, A. Akcakanat, et al.Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss Oncotarget, 11 (11) (2020), pp. 969-981

139 R. Dent, M. Oliveira, S.J. Isakoff, et al.Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer Breast Cancer Res Treat, 189 (2) (2021), pp. 377-386

140 S. Dawood, K. Broglio, A.U. Buzdar, et al.Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol, 28 (1) (2010), pp. 92-98

141 L.H. Hartwell, P. Szankasi, C.J. Roberts, et al.Integrating genetic approaches into the discovery of anticancer drugs Science, 278 (5340) (1997), pp. 1064-1068

142 D. Brunen, R. BernardsDrug therapy: exploiting synthetic lethality to improve cancer therapy Nat Rev Clin Oncol, 14 (6) (2017), pp. 331-332

143 N.J. O'Neil, M.L. Bailey, P. HieterSynthetic lethality and cancer Nat Rev Genet, 18 (10) (2017), pp. 613-623

144 W. Topatana, S. Juengpanich, S. Li, et al.Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation J Hematol Oncol, 13 (2020), p. 118

145 V. Doye, E.C. HurtGenetic approaches to nuclear pore structure and function Trends Genet, 11 (6) (1995), pp. 235-241

146 F. Fece de la Cruz, B.V. Gapp, S.M.B. NijmanSynthetic lethal vulnerabilities of cancer Annu Rev Pharmacol Toxicol, 55 (2015), pp. 513-531

147 T.R. Brummelkamp, R. BernardsNew tools for functional mammalian cancer genetics Nat Rev Cancer, 3 (10) (2003), pp. 781-789

148 H. Farmer, N. McCabe, C.J. Lord, et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature, 434 (7035) (2005), pp. 917-921

149 H.E. Bryant, N. Schultz, H.D. Thomas, et al.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature, 434 (7035) (2005), pp. 913-917

150 A.M. Mendes-Pereira, S.A. Martin, R. Brough, et al.Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med, 1 (6–7) (2009), pp. 315-322

151 X. Liu, E.K. Han, M. Anderson, et al.Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways Mol Cancer Res, 7 (10) (2009), pp. 1686-1692

152 B. McEllin, C.V. Camacho, B. Mukherjee, et al.PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors Cancer Res, 70 (13) (2010), pp. 5457-5464

153 R. Brough, J.R. Frankum, D. Sims, et al.Functional viability profiles of breast cancer Cancer Discov, 1 (3) (2011), pp. 260-273

154 A.M. Mendes-Pereira, C.J. Lord, A. AshworthNLK is a novel therapeutic target for PTEN deficient tumour cells PLoS One, 7 (10) (2012), Article e47249

155 T.R. Mereniuk, M.A.M. El Gendy, A.M. Mendes-Pereira, et al.Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase Mol Cancer Therapeut, 12 (10) (2013), pp. 2135-2144

156 S.M.A. Sadat, I.M. Paiva, Z. Shire, et al.A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3’-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer J Contr Release, 334 (2021), pp. 335-352

157 Z. Shire, M.R. Vakili, T.D.R. Morgan, et al.Nanoencapsulation of novel inhibitors of PNKP for selective sensitization to ionizing radiation and irinotecan and induction of synthetic lethality Mol Pharm, 15 (6) (2018), pp. 2316-2326

158 R. Abbotts, R. Jewell, J. Nsengimana, et al.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy Oncotarget, 5 (10) (2014), pp. 3273-3286

159 G. Saglio, A. Morotti, G. Mattioli, et al.Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia Ann N Y Acad Sci, 1028 (2004), pp. 423-431

160 A. Morotti, C. Panuzzo, S. Crivellaro, et al.BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP Leukemia, 28 (6) (2014), pp. 1326-1333

161 A. Morotti, C. Panuzzo, S. Crivellaro, et al.BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation Cell Cycle, 14 (7) (2015), pp. 973-979

162 N. McCabe, C. Hanna, S.M. Walker, et al.Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM Cancer Res, 75 (11) (2015), pp. 2159-2165

163 K. Li, H. Yan, W. Guo, et al.ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin Exp Cell Res, 366 (1) (2018), pp. 24-33

164 J.A. Benitez, J. Ma, M. D'Antonio, et al.PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3 Nat Commun, 8 (2017), Article 15223

165 D. Zhao, X. Lu, G. Wang, et al.Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer Nature, 542 (7642) (2017), pp. 484-488

166 D. Mathur, E. Stratikopoulos, S. Ozturk, et al.PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition Cancer Discov, 7 (4) (2017), pp. 380-390

167 S. Ozturk, D. Mathur, R.W. Zhou, et al.Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer Prostate Cancer Prostatic Dis, 23 (4) (2020), pp. 718-723

168 Y.C. Tang, S.C. Ho, E. Tan, et al.Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer Breast Cancer Res, 20 (1) (2018), p. 22

169 N. Al-Subhi, R. Ali, T. Abdel-Fatah, et al.Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy Breast Cancer Res Treat, 169 (2) (2018), pp. 277-286

170 N. Chatterjee, E. Pazarentzos, M.K. Mayekar, et al.Synthetic essentiality of metabolic regulator PDHK1 in PTEN-deficient cells and cancers Cell Rep, 28 (9) (2019), pp. 2317-2330.e8

171 P. Chen, D. Zhao, J. Li, et al.Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma Cancer Cell, 35 (6) (2019), pp. 868-884.e6

172 A. Ertay, H. Liu, D. Liu, et al.WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer Cell Death Dis, 11 (11) (2020), p. 1001

173 Y. Liu, E.J. Yang, C. Shi, et al.Histone acetyltransferase (HAT) P300/CBP inhibitors induce synthetic lethality in PTEN-deficient colorectal cancer cells through destabilizing AKT Int J Biol Sci, 16 (11) (2020), pp. 1774-1784

174 A. Huang, L.A. Garraway, A. Ashworth, et al.Synthetic lethality as an engine for cancer drug target discovery Nat Rev Drug Discov, 19 (1) (2020), pp. 23-38

175 H. Li, Z.Y. Liu, N. Wu, et al.PARP inhibitor resistance: the underlying mechanisms and clinical implications Mol Cancer, 19 (2020), p. 107

176 S. Li, W. Topatana, S. Juengpanich, et al.Development of synthetic lethality in cancer: molecular and cellular classification Signal Transduct Targeted Ther, 5 (2020), p. 241

177 A.A. Ku, H.M. Hu, X. Zhao, et al.Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility Nat Commun, 11 (2020), p. 2375

178 N. McGranahan, C. SwantonClonal heterogeneity and tumor evolution: past, present, and the future Cell, 168 (4) (2017), pp. 613-628

179 J.D. Martin, H. Cabral, T. Stylianopoulos, et al.Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges Nat Rev Clin Oncol, 17 (4) (2020), pp. 251-266

180 M.S. GoldbergImproving cancer immunotherapy through nanotechnology Nat Rev Cancer, 19 (10) (2019), pp. 587-602

181 R.S. Riley, C.H. June, R. Langer, et al.Delivery technologies for cancer immunotherapy Nat Rev Drug Discov, 18 (3) (2019), pp. 175-196

182 C. Du, Y. Qi, Y. Zhang, et al.Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation ACS Nano, 12 (11) (2018), pp. 10785-10796

183 K. Ebeid, X. Meng, K.W. Thiel, et al.Synthetically lethal nanoparticles for treatment of endometrial cancer Nat Nanotechnol, 13 (1) (2018), pp. 72-81

184 C. Rolfo, E. GiovannettiA synthetic lethal bullet Nat Nanotechnol, 13 (1) (2018), pp. 6-7

185 T.J. JerdePhosphatase and tensin homologue: novel regulation by developmental signaling J Signal Transduct, 2015 (2015), Article 282567

186 X. Wang, X. JiangPTEN: a default gate-keeping tumor suppressor with a versatile tail Cell Res, 18 (8) (2008), pp. 807-816

187 B.T. Hennessy, D.L. Smith, P.T. Ram, et al.Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov, 4 (12) (2005), pp. 988-1004